Alina Bogdanov, MA
Alina Bogdanov is a data expert, staying true to the name in providing expertise in evaluating and understanding the intricacies of Veradigm’s wide range of data products. She lends her expertise across Veradigm departments, helping to solve complex technical questions with her ability to dive deep in the data and facilitate cross-team discussions around project implementation and process.
AREA OF EXPERTISE
Real World Data / Evidence Quantitative Programming Study ImplementationAlina is the Director of Data Analytics, Real World Evidence at Veradigm. Ms. Bogdanov is a healthcare researcher with over 15 years of experience in health outcomes and healthcare quality research. In her role, she oversees a team of research quantitative programmers, biostatisticians, and data scientists conducting real-world studies using the Veradigm Network EHR, Registry, and linked administrative claims datasets. Beyond study work, she leads her team in investigating and evaluating the fitness for purpose of new and existing datasets and establishing high-quality, repeatable processes for RWE work.
Ms. Bogdanov joined Veradigm from Practice Fusion, where she was also responsible for the full analytics life cycle around ad campaigns (from selecting target and control cohorts to campaign effectiveness measurements) as well as maintaining multiple sales- and leadership- facing dashboards. Prior to that she was at Acumen LLC, where she used Medicare and Medicaid claims data to tackle problems such as bundled payment policy monitoring, quality program evaluation, fraud waste and abuse, and emergency response. Ms. Bogdanov holds an MA in Economics from Boston University.
Outside of work you can find Alina baking her own sourdough bread and exploring New Jersey with her family.
References to published articles by this expert
- Kopel H, Nguyen VH, Bogdanov A, Winer I, Boileau C, Ducruet T, Zeng N, Winer-Jones JP, Esposito DB, Bausch-Jurken M, Beck E, Bonafede M, Mansi JA. Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines Mrna-1273.222 andBNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States. Vaccines 2024; 12: 1107.
- Imran M, Mills C, McDermott KW, Dean A, Bogdanov A, McGovern I, Haag M. Relative Effectiveness of Adjuvanted versus Non-Adjuvanted Influenza Vaccines in Older Adults with Risk Factors for Influenza Complications during the 2019–2020 U.S. Influenza Season. Vaccine 2024; 42: 126316.
- Stein AN, Mills CW, McGovern I, McDermott KW, Dean A, Bogdanov AN, Sullivan SG, Haag MDM. Relative Vaccine Effectiveness of Cell- vs Egg-Based Quadrivalent Influenza Vaccine against Test-Confirmed Influenza over 3 Seasons between 2017 and 2020 in the United States. Open Forum Infect Dis 2024; 11: ofae175.
- McGovern I, Cappell K, Bogdanov AN, Haag MDM. The Number of Influenza Risk Factors Informs an Adult’s Increased Potential of Severe Influenza Outcomes: A Multi-Season Cohort Study from 2015 to 2020. Open Forum Infectious Diseases 2024; ofae203.
- Kopel H, Araujo AB, Bogdanov A, Zeng N, Winer I, Winer-Jones J, Lu T, Marks MA, Bonafede M, Nguyen VH, Martin D, Mansi JA. Effectiveness of the 2023-2024 Omicron XBB.1.5-Containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-Related Hospitalizations and Medical Encounters among Adults in the United States. Open Forum Infect Dis 2024; 11: ofae695.
- Imran M, Mills CW, McDermott KW, Dean A, Bogdanov A, McGovern I, Haag MDM. Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine vs High-Dose Influenza Vaccine in Older Adults with Influenza Risk Factors during the 2019-2020 U.S. Influenza Season. Open Forum Infect Dis 2024; 11: ofae459.
- Kopel H, Bogdanov A, Winer-Jones JP, Adams C, Winer IH, Bonafede M, Nguyen VH, Mansi JA. Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall–Winter 2022–2023: A Cross-Sectional Retrospective Study. Diseases 2024; 12: 16.
- McGovern I, Cappell K, Bogdanov AN, Haag MDM. Incidence of Influenza-Related Medical Encounters and the Associated Healthcare Resource Use and Complications across Adult Age Groups in the United States during the 2015-2020 Influenza Seasons. Clin Infect Dis 2024; 79: 778–786.